Bal Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Bal Pharma share price target 2026 is Rs 105, based on analyst estimates and the FY27 earnings recovery thesis. Q4 FY26 results announced May 30, 2026 are the immediate trigger for re-rating Bal Pharma (NSE: BALPHARMA). This article covers the complete Bal Pharma share price target analysis including sector tailwinds, key risks, and the bull and bear case scenarios.

Click Here – Get Free Investment Predictions

Bal Pharma Company Overview

Bal Pharma (NSE: BALPHARMA) is a Bengaluru-based integrated pharma company making tablets, capsules, oral liquids, and injectables with API manufacturing at Bommasandra. At CMP Rs 87.11 against a 52 week range of Rs 60 to Rs 157, the stock trades at a meaningful discount to its 52 week high. Market capitalisation stands at Rs 246 crore with a trailing PE of 20x.

Parameter	Value
NSE Ticker	BALPHARMA
Sector	Pharmaceutical Formulations and APIs
CMP (May 30, 2026)	Rs 87.11
52 Week High	Rs 157
52 Week Low	Rs 60
Market Cap	Rs 246 crore
Trailing PE	20x
12-Month Analyst Target	Rs 105
Bull Case Target	Rs 125
Bear Case Target	Rs 69.7

Why Is the Bal Pharma Share Price Target Set at Rs 105 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Bal Pharma share price target 2026 of Rs 105 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results confirming the recovery trajectory are the most direct catalyst for re-rating from CMP Rs 87.11 toward the Bal Pharma share price target of Rs 105.

Structural Sector Tailwinds in Pharmaceutical Formulations and APIs

The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s strong domestic demand, PLI scheme support, and rising corporate investment. Bal Pharma’s market position creates a structural growth runway supporting the Bal Pharma share price target consensus of Rs 105 and the bull case of Rs 125.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle, which began in early 2026, reduces Bal Pharma’s borrowing costs and stimulates demand across end markets. Lower interest costs improve EPS trajectory, directly supporting the Bal Pharma share price target 2026 of Rs 105.

Union Budget 2026-27 Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Bal Pharma’s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Bal Pharma share price target of Rs 105.

Improving FII Flows Post the April 2026 Tariff Shock

As global macro conditions normalise post the April 2026 US tariff event, FII flows into quality Indian equities are recovering through FY27. At 20x PE, Bal Pharma is positioned as a beneficiary of institutional reallocation supporting the path to Rs 105.

Bal Pharma Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Bal Pharma Share Price Target: 3 to 6 Months

The near-term Bal Pharma share price target is anchored to support near the 52 week low of Rs 60. A confirmed Q4 FY26 earnings recovery and positive FY27 guidance are the triggers for an initial 10 to 15 percent re-rating toward Rs 105.

12-Month Bal Pharma Share Price Target 2026

The 12-month Bal Pharma share price target 2026 is Rs 105, implying approximately 20 percent upside from CMP Rs 87.11. This base case assumes in-line FY27 earnings delivery and partial FII flow normalisation. Track live on NSE ticker BALPHARMA.

Long Term Bal Pharma Share Price Target: FY27 to FY28

For investors with a 2 to 3 year horizon, the long-term Bal Pharma share price target is Rs 125 in the bull case, assuming full earnings delivery through FY27 to FY28 and sector re-rating in the Pharmaceutical Formulations and APIs space.

Bull Case and Bear Case for the Bal Pharma Share Price Target

Bull Case Bal Pharma Share Price Target: Rs 125

The bull case for the Bal Pharma share price target of Rs 125 materialises when FY27 earnings beat analyst estimates, sector tailwinds accelerate, and FII flows return strongly to Indian equities. The stock re-rates toward higher peer multiples, making Rs 125 achievable within FY28.

Bear Case Bal Pharma Share Price Target: Rs 69.7

The bear case sees the Bal Pharma share price target testing Rs 69.7 if FY27 earnings disappoint and FII outflows persist. At Rs 69.7, the stock approaches the 52 week low support of Rs 60, requiring a full reassessment of the investment thesis.

Scenario	Target	Key Conditions
Bull Case	Rs 125	FY27 earnings beat, sector re-rating, strong FII inflows
Base Case	Rs 105	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 69.7	FY27 earnings miss, guidance cut, sustained FII outflows

Key Risks to the Bal Pharma Share Price Target 2026

US Tariff and Global Macro Risk

The 26 percent US reciprocal tariff announced April 2, 2026 triggered FII outflows across Indian equities. Prolonged trade tension or a global demand slowdown remains the most prominent macro risk to the Bal Pharma share price target 2026 of Rs 105.

Valuation and Earnings Miss Risk

Any FY27 earnings miss or guidance cut could trigger multiple compression, posing a direct risk to the Bal Pharma share price target of Rs 105. Monitoring quarterly results closely is essential for investors in Bal Pharma.

Competitive Pressure in Pharmaceutical Formulations and APIs

Intensifying competition in the Pharmaceutical Formulations and APIs sector could compress Bal Pharma’s pricing power and market share over the medium term, which must be factored into any assessment of the Bal Pharma share price target of Rs 105.

FII Selling Pressure and Liquidity Risk

Sustained FII outflows from Indian equities can delay re-rating toward the Bal Pharma share price target of Rs 105 regardless of company-level operational improvement through FY27.

How to Invest in Bal Pharma

Check the Univest Screener for live data

Begin by reviewing Bal Pharma’s Q4 FY26 results, annual report, and FY27 guidance statements before forming a view on the Bal Pharma share price target of Rs 105. Focus on revenue growth trajectory, margin trends, and management commentary on sector headwinds and opportunities.

Open a Demat and trading account with a SEBI registered stockbroker to buy Bal Pharma (NSE: BALPHARMA) with full regulatory protection. Ensure KYC is complete and understand the Pharmaceutical Formulations and APIs sector dynamics before executing any position.

Plan your entry near the 52 week low support of Rs 60. A confirmed Q4 FY26 earnings uptick and positive FY27 guidance would strengthen the entry case for the Bal Pharma share price target of Rs 105. Set a disciplined stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk, especially in smaller-cap Pharmaceutical Formulations and APIs companies where liquidity and volatility can amplify losses.

Always consult a SEBI registered financial advisor before investing based on any Bal Pharma share price target estimate. A registered advisor personalises recommendations based on your risk profile and financial goals. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Bal Pharma’s live price and get daily stock recommendations.

FAQs on Bal Pharma Share Price Target 2026

What is the Bal Pharma share price target for 2026?

Ans. The Bal Pharma share price target 2026 is Rs 105, implying approximately 20 percent upside from CMP Rs 87.11. The bull case target is Rs 125 and the bear case target is Rs 69.7.

Is Bal Pharma a good buy at the current price of Rs 87.11?

Ans. At Rs 87.11, Bal Pharma offers potential upside to the share price target of Rs 105 if FY27 earnings recover as projected. Consult a SEBI registered financial advisor before making any investment decision.

What is the 52 week high and low of Bal Pharma?

Ans. The 52 week high of Bal Pharma is Rs 157 and the 52 week low is Rs 60. At CMP Rs 87.11, the stock offers upside potential toward the 12-month share price target of Rs 105.

What are the key risks to the Bal Pharma share price target 2026?

Ans. Key risks to the Bal Pharma share price target of Rs 105 include an FY27 earnings miss, US tariff-driven FII outflows, competitive pressure in Pharmaceutical Formulations and APIs, and broader market volatility.

What are the main catalysts for the Bal Pharma share price target?

Ans. Primary catalysts include FY27 PAT recovery, structural tailwinds in Pharmaceutical Formulations and APIs, RBI rate cut support, Union Budget 2026-27 policy uplift, and FII flow normalisation into Indian equities through FY27.

What is the Bal Pharma share price target for 2027?

Ans. The long-term Bal Pharma share price target for FY27 to FY28 is Rs 125 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.